If you’re looking to invest in healthcare stocks, Pfizer and Viking Therapeutics are worth considering. Pfizer has seen significant growth post-pandemic, with acquisitions boosting its pipeline. Viking Therapeutics is developing a drug for the GLP-1 market, showing promise in clinical trials. Both stocks offer long-term potential for investors in the healthcare sector.

Pfizer has experienced a resurgence with its COVID-19 vaccine success, leading to substantial growth. The company has made strategic acquisitions to bolster its drug pipeline and offset patent expirations. Additionally, Pfizer has commercialized new products and is focusing on non-COVID growth areas, ensuring its continued success in the healthcare industry.

Viking Therapeutics is a clinical-stage biopharmaceutical company with a promising lead candidate, VK2735. This drug targets the GLP-1 and GIP receptors, showing potential for weight loss and diabetes improvement. With a diversified pipeline and robust cash position, Viking Therapeutics offers a compelling option for long-term investors seeking growth in the healthcare sector.

Read more at Yahoo Finance: 2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon